Open Label Study of Adalimumab in Subjects Who Have a Sub-Optimal Response to Systemic Therapy or Phototherapy.
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2012
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 20 Mar 2012 Results of an indirect comparison economic comparison of the ACCORD and M10-238 studies presented at the 70th Annual Meeting of the American Academy of Dermatology.
- 27 May 2010 Actual number of patients added to 152 as reported by ClinicalTrials.gov.
- 03 Oct 2009 New trial record.